卵巢癌组织学亚型的 hRad17 差异表达。

Differential hRad17 expression by histologic subtype of ovarian cancer.

机构信息

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, SC, USA.

出版信息

J Ovarian Res. 2011 Mar 30;4(1):6. doi: 10.1186/1757-2215-4-6.

DOI:10.1186/1757-2215-4-6

PMID:21450056

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3077316/

Abstract

BACKGROUND

In the search for unique ovarian cancer biomarkers, ovarian specific cDNA microarray analysis identified hRad17, a cell cycle checkpoint protein, as over-expressed in ovarian cancer. The aim of this study was to validate this expression.

METHODS

Immunohistochemistry was performed on 72 serous, 19 endometrioid, 10 clear cell, and 6 mucinous ovarian cancers, 9 benign ovarian tumors, and 6 normal ovarian tissue sections using an anti-hRad17 antibody. Western blot analysis and quantitative PCR were performed using cell lysates and total RNA prepared from 17 ovarian cancer cell lines and 6 normal ovarian epithelial cell cultures (HOSE).

RESULTS

Antibody staining confirmed upregulation of hRad17 in 49.5% of ovarian cancer cases. Immunohistochemistry demonstrated that only 42% of serous and 47% of endometrioid subtypes showed overexpression compared to 80% of clear cell and 100% of mucinous cancers. Western blot confirmed overexpression of hRad17 in cancer cell lines compared to HOSE. Quantitative PCR demonstrated an upregulation of hRad17 RNA by 1.5-7 fold. hRad17 RNA expression differed by subtype.

CONCLUSIONS

hRad17 is over-expressed in ovarian cancer. This over-expression varies by subtype suggesting a role in the pathogenesis of these types. Functional studies are needed to determine the potential role of this protein in ovarian cancer.

摘要

背景

在寻找独特的卵巢癌生物标志物的过程中，卵巢特异性 cDNA 微阵列分析发现 hRad17（细胞周期检查点蛋白）在卵巢癌中过表达。本研究旨在验证这种表达。

方法

使用抗 hRad17 抗体对 72 例浆液性、19 例子宫内膜样、10 例透明细胞和 6 例黏液性卵巢癌、9 例良性卵巢肿瘤和 6 例正常卵巢组织切片进行免疫组织化学染色。使用来自 17 种卵巢癌细胞系和 6 种正常卵巢上皮细胞培养物（HOSE）的细胞裂解物和总 RNA 进行 Western blot 分析和定量 PCR。

结果

抗体染色证实 hRad17 在 49.5%的卵巢癌病例中上调。免疫组织化学显示，与透明细胞癌的 80%和黏液性癌的 100%相比，只有 42%的浆液性和 47%的子宫内膜样亚型显示过表达。Western blot 证实 hRad17 在癌细胞系中过表达，而在 HOSE 中则没有。定量 PCR 显示 hRad17 RNA 上调 1.5-7 倍。hRad17 RNA 表达因亚型而异。